摘要
目的探讨沙库巴曲缬沙坦、达格列净联合用药治疗射血分数保留型心力衰竭疾病的临床效果与安全性。方法回顾性选取2019年1月—2022年7月东台市人民医院接诊治疗的射血分数保留型心力衰竭患者60例患者的临床资料进行分析研究,按照随机抽签奇偶结果分为对照组(奇数签,30例)与观察组(偶数签,30例)。对照组患者治疗方案为单独应用达格列净,观察组患者治疗方案为采取沙库巴曲缬沙坦、达格列净双药联合。比较治疗效果,治疗前后心功能、心肌损害指标检测结果,治疗期间不良反应发生情况。结果经联合用药治疗后观察组患者总有效率为96.67%高于对照组,差异有统计学意义(χ^(2)=7.680,P<0.05)。同时治疗后观察组患者心功能指标中E/A高于对照组,LVEDD、DT、LVMI均低于对照组,差异有统计学意义(P<0.05);治疗后,心肌损伤指标NT-proBNP、TnI低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论临床治疗射血分数保留型心力衰竭疾病可采取沙库巴曲缬沙坦、达格列净双药联合方案,有效提高疗效、促进心功能恢复的同时,不增加不良反应,安全性理想。
Objective To investigate the clinical effect and safety of Sacubitril Valsartan combined with Dapagliflozin in the treatment of heart failure with preserved ejection fraction.Methods The clinical data of 60 patients with ejection fraction preserved heart failure who were treated at Dongtai People's Hospital from January 2019 to July 2022 were retrospectively selected for analysis and research.They were randomly divided into a control group(odd numbered,30 cases)and an observation group(even numbered,30 cases)based on the odd and even results of a random draw.The treatment plan of the control group was Dapagliflozin alone,and the treatment plan of the observation group was the combination of Sacubitril Valsartan and Dapagliflozin.Compare the treatment effects,test results of cardiac function and myocardial damage indicators before and after treatment,and the occurrence of adverse reactions during the treatment period.Results The total effective rate of the observation group was 96.67%higher than that of the control group after combined treatment,the difference was statistically significant(χ^(2)=7.680,P<0.05).At the same time,after treatment,E/A in the cardiac function indexes of the observation group was higher than that of the control group,LVEDD,DT,LVMI were lower than those of the control group,the difference was statistically significant(P<0.05);after treatment myocardial injury indexes NT-proBNP,TnI were lower than those of the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion In the clinical treatment of heart failure with preserved ejection fraction,the combination of Sacubitril valsartan and Dapagliflozin can effectively improve the curative effect.While promoting the recovery of heart function,it does not increase adverse reactions,and has ideal safety.
作者
邱珺
QIU Jun(Department of Cardiology,Dongtai People's Hospital,Dongtai,Jiangsu Province,224200 China)
出处
《中外医疗》
2023年第9期141-145,共5页
China & Foreign Medical Treatment
关键词
沙库巴曲缬沙坦
达格列净
射血分数保留型心力衰竭
心功能
Sacubitril Valsartan
Dapagliflozin
Heart failure with preserved ejection fraction
Heart function
